Back to search results

Observational Study for Pancreatic Cancer Screening in Individuals with Genetic Mutations

This observational study is looking at people who have specific genetic mutations (changes in genes like BRCA1, BRCA2, ATM, or PALB2) that might increase their risk for pancreatic cancer. The study wants to see how often abnormal findings show up on routine imaging tests like Magnetic Resonance Imaging (MRI) and Endoscopic Ultrasound (EUS) in these individuals. You would undergo procedures like blood, tissue, and saliva collection, MRI, Magnetic Resonance Cholangiopancreatography (MRCP), and EUS. You would also complete questionnaires about your knowledge, worry, and perceived risk of pancreatic cancer. The study aims to understand if these screening methods can detect early signs of pancreatic cancer and its precursors. This information could help improve future screening and treatment for pancreatic cancer. The study is currently unclear on its recruitment status and plans to enroll 250 participants.

Study design
This is an observational study with a planned enrollment of 250 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo MRI/MRCP or alternating MRI/MRCP and EUS annually for up to 10 years, or complete questionnaires and provide blood, saliva, and tissue samples.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 10 years to measure abnormal MRI findings.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05058846

Pilot Study of Pancreatic Cancer Screening

Active, Not Recruiting
Not specifiedAges 18+Observational
University of California, San Francisco
~250 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:Biospecimen CollectionMagnetic Resonance CholangiopancreatographyMagnetic Resonance ImagingEndoscopic ultrasoundQuestionnaires

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings
Measured over Up to 10 years

Conditions

Pancreatic Carcinoma

Explore related trials

Pancreatic CarcinomaATM GeneBRCA1 GeneBRCA2 GenePartner and Localizer of BRCA2

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Pamela N Munster, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation
No strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer)
Age \>= 50 years old at time of consent.
Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation
Has strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer)
Age \>= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family)

Exclusion

Prior or active pancreatic cancer.
Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.

What this trial measures

  • Proportion of participants with of abnormal magnetic resonance imaging (MRI) findingsUp to 10 years

    Proportion of participants with an abnormal MRI finding will be reported as an event. An estimated event rate of 19% in participants with a strong family history (FH) of pancreatic cancer and 10% in those participants without a strong FH of pancreatic cancer and 95% binomial confidence intervals (CIs) will also be reported.